Indications and uses
Helps Prevent Sunburn If Used As Directed With Other Sun Protection Measures (See Directions), Decreases The Risk Of Skin Cancer And Early Skin Aging Caused By The Sun
Helps Prevent Sunburn If Used As Directed With Other Sun Protection Measures (See Directions), Decreases The Risk Of Skin Cancer And Early Skin Aging Caused By The Sun
Apply liberally 15 minutes before sun exposure Apply to all skin exposed to the sun Children under 6 months: Ask a doctor Sun Protection Measures. Spending time in the sun increases your risk of skin cancer and early skin aging. To decrease this risk, regularly use a sunscreen with a broad spectrum SPF of 15 or higher and other sun protection measures including: limit time in the sun, especially from 10 a.m. – 2 ...
TITANIUM DIOXIDE 2.5%
Sunscreen
For external use only.
If product is swallowed, get medical help or contact a Poison Control Center right away.
AQUA/WATER/EAU, CYCLOPENTASILOXANE, ISONONYL ISONONANOATE, BUTYLENE GLYCOL, TALC, DIMETHICONE, POLYGLYCERYL-3 RICINOLEATE, SORBITAN OLEATE, PEG-30 DIPOLYHYDROXYSTEARATE, MAGNESIUM SULFATE, SILICA, PHENOXYETHANOL, MAGNESIUM STEARATE, POLYHYDROXYSTEARIC ACID, DIMETHICONOL, DISTEARDIMONIUM HECTORITE, IMETHICONE CROSSPOLYMER, PARFUM/FRAGRANCE, SORBIC ACID, AVENA SATIVA (OAT) KERNEL EXTRACT, DIMETHICONE/VINYL DIMETHICONE CROSSPOLYMER, HYDROXYETHYL UREA, LAUROYL LYSINE, CAMELLIA SINENSIS LEAF EXTRACT, ALGIN, SODIUM BENZOATE, ACACIA SENEGAL GUM, LAPSANA COMMUNIS FLOWER/LEAF/STEM EXTRACT, PLANTAGO MAJOR SEED EXTRACT, ALPHAISOMETHYL IONONE, LINALOOL, HEXYL CINNAMAL, LIMONENE.
± / MAY CONTAIN/PEUT CONTENIR: [CI 77891/TITANIUM DIOXIDE . MICA . CI 77491/CI 77492/CI 77499/ IRON OXIDES]. [M2060A]
Call 1-866-252-7467 (In the US) Monday-Friday, 8 a.m. to 5 p.m.
The perfect match between make-up and skin care. A creamy rich foundation that combines exceptional skin firming and age-fighting ingredients for a visibly younger-looking complexion. Delivers a smooth, more radiant, even complexion.
Satin finish - Medium coverage - All skin types.
Oil-free. Non-comedogenic. Dermatologist tested.
CLARINS PARIS 92200 Neuilly 95300 Pontoise - France Made in France
CLARINS PARIS 105 Teint Broad Spectrum SPF 15 Titanium Dioxide - Sunscreen Extra-Firming Foundation 30 mL 1.1 Oz. Net Wt.
| Ingredient | Type | UNII | SPL version | Uploaded |
|---|---|---|---|---|
| TITANIUM DIOXIDE | ACTIVE INGREDIENT | 15FIX9V2JP | 2 | |
| TITANIUM DIOXIDE | ACTIVE MOIETY | 15FIX9V2JP | 2 | |
| .ALPHA.-HEXYLCINNAMALDEHYDE | INACTIVE INGREDIENT | 7X6O37OK2I | 2 | |
| ACACIA | INACTIVE INGREDIENT | 5C5403N26O | 2 | |
| BUTYLENE GLYCOL | INACTIVE INGREDIENT | 3XUS85K0RA | 2 | |
| CYCLOMETHICONE 5 | INACTIVE INGREDIENT | 0THT5PCI0R | 2 | |
| DIMETHICONE | INACTIVE INGREDIENT | 92RU3N3Y1O | 2 | |
| FERRIC OXIDE RED | INACTIVE INGREDIENT | 1K09F3G675 | 2 | |
| GREEN TEA LEAF | INACTIVE INGREDIENT | W2ZU1RY8B0 | 2 | |
| HYDROXYETHYL UREA | INACTIVE INGREDIENT | MBQ7DDQ7AR | 2 | |
| ISOMETHYL-.ALPHA.-IONONE | INACTIVE INGREDIENT | 9XP4LC555B | 2 | |
| ISONONYL ISONONANOATE | INACTIVE INGREDIENT | S4V5BS6GCX | 2 | |
| LAPSANA COMMUNIS FLOWERING TOP | INACTIVE INGREDIENT | T9B77O7PZA | 2 | |
| LAUROYL LYSINE | INACTIVE INGREDIENT | 113171Q70B | 2 | |
| LINALOOL, (+/-)- | INACTIVE INGREDIENT | D81QY6I88E | 2 | |
| MAGNESIUM STEARATE | INACTIVE INGREDIENT | 70097M6I30 | 2 | |
| MAGNESIUM SULFATE | INACTIVE INGREDIENT | DE08037SAB | 2 | |
| MICA | INACTIVE INGREDIENT | V8A1AW0880 | 2 | |
| OAT | INACTIVE INGREDIENT | Z6J799EAJK | 2 | |
| PEG-30 DIPOLYHYDROXYSTEARATE | INACTIVE INGREDIENT | 9713Q0S7FO | 2 | |
| PHENOXYETHANOL | INACTIVE INGREDIENT | HIE492ZZ3T | 2 | |
| PLANTAGO MAJOR SEED | INACTIVE INGREDIENT | YP0NFQ834U | 2 | |
| POLYGLYCERYL-3 RICINOLEATE | INACTIVE INGREDIENT | MZQ63P0N0W | 2 | |
| SILICON DIOXIDE | INACTIVE INGREDIENT | ETJ7Z6XBU4 | 2 | |
| SODIUM ALGINATE | INACTIVE INGREDIENT | C269C4G2ZQ | 2 | |
| SODIUM BENZOATE | INACTIVE INGREDIENT | OJ245FE5EU | 2 | |
| SORBIC ACID | INACTIVE INGREDIENT | X045WJ989B | 2 | |
| SORBITAN MONOOLEATE | INACTIVE INGREDIENT | 06XEA2VD56 | 2 | |
| TALC | INACTIVE INGREDIENT | 7SEV7J4R1U | 2 | |
| WATER | INACTIVE INGREDIENT | 059QF0KO0R | 2 |
Every source-derived product name is available through these pages.
| Product NDC | Package NDC |
|---|---|
| 58668-0679 | 58668-0679-1 |
Every source-derived ingredient row is available through these pages.
Inactive Ingredient Database values describe FDA-listed use contexts. The match method and ambiguity count are shown because ingredient names, routes, and dosage forms are not always unique. Browse recovered IID releases and source provenance.
| DailyMed ingredient | IID ingredient | UNII | Dosage form / route | Potency | Maximum daily exposure | Match |
|---|---|---|---|---|---|---|
| MAGNESIUM SULFATE | MAGNESIUM SULFATE | DE08037SAB | CAPSULE / ORAL | NA | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | TABLET, DELAYED RELEASE / ORAL | 0.34 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | SUSPENSION / ORAL | 40 mg | ||
| TALC | TALC | 7SEV7J4R1U | TABLET / ORAL | 1000 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GEL / NASAL | 20 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | LOTION / TOPICAL | 4 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | PASTE / ORAL | 28 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | WAFER / ORAL | 66 mg | ||
| TALC | TALC | 7SEV7J4R1U | POWDER, FOR SUSPENSION / ORAL | 735 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | AEROSOL, FOAM / TOPICAL | 6 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | GEL / TOPICAL | 14 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | CAPSULE / ORAL | 256.4 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET / SUBLINGUAL | 10 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE, COATED PELLETS / ORAL | 69 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | SOLUTION/ DROPS / OPHTHALMIC | 0.2 %w/v | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | SYSTEM / INTRAVITREAL | 0.02 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SOLUTION / ORAL | 336 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | FILM, SOLUBLE / BUCCAL | 3 mg | ||
| SORBIC ACID | SORBIC ACID | X045WJ989B | SYRUP / ORAL | 80 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / BUCCAL | 17.5 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET, ORALLY DISINTEGRATING, DELAYED RELEASE / ORAL | 47 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | TABLET / SUBLINGUAL | 17.5 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | AEROSOL, FOAM / TOPICAL | 72 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SPONGE / TOPICAL | NA | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / ORAL | 602 mg | ||
| SORBITAN MONOOLEATE | SORBITAN MONOOLEATE | 06XEA2VD56 | SYSTEM / TRANSDERMAL | 2.33 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | DROPS / ORAL | NA | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / SUBLINGUAL | 1 mg | ||
| TALC | TALC | 7SEV7J4R1U | OINTMENT / TOPICAL | 74.6 %w/w | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE / ORAL | 629 mg | ||
| PHENOXYETHANOL | PHENOXYETHANOL | HIE492ZZ3T | CREAM, AUGMENTED / TOPICAL | 10 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET / SUBLINGUAL | 9.1 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | CAPSULE / ORAL | 5 mg | ||
| SORBITAN MONOOLEATE | SORBITAN MONOOLEATE | 06XEA2VD56 | FILM, EXTENDED RELEASE / TRANSDERMAL | NA | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, DELAYED RELEASE / ORAL | 420 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUPPOSITORY / RECTAL | 14 mg | ||
| TALC | TALC | 7SEV7J4R1U | CAPSULE, EXTENDED RELEASE / ORAL | 5119 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | POWDER / RESPIRATORY (INHALATION) | NA | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SUSPENSION / ORAL | 320 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | GRANULE, FOR SUSPENSION / ORAL | 200 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, EXTENDED RELEASE / ORAL | 450 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | SYSTEM / TOPICAL | 2 mg | ||
| ACACIA | ACACIA | 5C5403N26O | TABLET, EXTENDED RELEASE / ORAL | 34.4 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, FILM COATED, EXTENDED RELEASE / ORAL | 336 mg | ||
| ACACIA | ACACIA | 5C5403N26O | SUSPENSION / INTRAMUSCULAR | 1 mg | ||
| SORBITAN MONOOLEATE | SORBITAN MONOOLEATE | 06XEA2VD56 | EMULSION / TOPICAL | 34050 mg | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | LIQUID / TOPICAL | 0.25 %w/w | ||
| TALC | TALC | 7SEV7J4R1U | GRANULE, DELAYED RELEASE / ORAL | 525 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SYSTEM / TRANSDERMAL | 35 mg | ||
| CYCLOMETHICONE 5 | CYCLOMETHICONE 5 | 0THT5PCI0R | AEROSOL / TOPICAL | 2.5 %w/w | ||
| SODIUM ALGINATE | SODIUM ALGINATE | C269C4G2ZQ | LOZENGE / ORAL | 1274 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | TABLET, ORALLY DISINTEGRATING / ORAL | 68 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | GRANULE, FOR SUSPENSION / ORAL | 14 mg | ||
| FERRIC OXIDE RED | FERRIC OXIDE RED | 1K09F3G675 | TABLET / BUCCAL | 0.4 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | CAPSULE / ORAL | 300 mg | ||
| SODIUM BENZOATE | SODIUM BENZOATE | OJ245FE5EU | CREAM / TOPICAL | 0.2 %w/w | ||
| ACACIA | ACACIA | 5C5403N26O | CAPSULE / ORAL | 20 mg | ||
| MAGNESIUM STEARATE | MAGNESIUM STEARATE | 70097M6I30 | LOZENGE / TRANSMUCOSAL | 100 mg | ||
| SILICON DIOXIDE | SILICON DIOXIDE | ETJ7Z6XBU4 | SUSPENSION, EXTENDED RELEASE / ORAL | 70 mg | ||
| SORBITAN MONOOLEATE | SORBITAN MONOOLEATE | 06XEA2VD56 | GEL / TOPICAL | 20 mg |
OpenFDA label data provides additional search and identifier links. DailyMed’s Structured Product Label is the canonical label on FDA.report. Matching records are deduplicated before they are shown below.
| Brand | Generic | Manufacturer | SPL set ID | Effective date | Available safety fields | Join |
|---|---|---|---|---|---|---|
| d0420ea1-2a0b-2565-e053-2a95a90ad221 | a52981da-511e-489f-9dff-381e426d0a22 | 2021-11-08 | Warnings | a52981da-511e-489f-9dff-381e426d0a22 |
Adverse event summaries are temporarily unavailable. Other product information remains available.